Skip to content

Advertisement

  • Poster presentation
  • Open Access

Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer

  • 1,
  • 2,
  • 3,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20131(Suppl 1):P55

https://doi.org/10.1186/2051-1426-1-S1-P55

Published: 7 November 2013

Keywords

  • Prostate Cancer
  • Gene Expression Profile
  • Affymetrix Microarray
  • Bivalent Vaccine
  • Identify Gene Expression

Immunotherapy represents a novel treatment approach for cancer; however, a longer maturation time and the lack of immunological markers are major obstacles in the development and characterization of immunological therapies. This study aims to identify gene expression profile on CD8+ T cells between the responder (completely regressed tumors) and non-responder (progressively growing tumors) groups of mice helpful in predicting the outcome of immunotherapy treatment. Using a preclinical mouse model for prostate cancer, subcutaneous tumors were established and the mice were treated with Ad-PSA+PSCA bivalent vaccine. Splenic CD8+ T cells purified from the responder and non-responder groups of mice were subjected to Affymetrix microarray to obtain gene expression profile. Pooling the data sets from two independent experiments revealed an up-regulation of 85 genes (>2.0 fold; p =2.7e-63) and down-regulation of 1768 gene (>2.0 fold; p =1.0e-63) in CD8+ T cells from the non-responder mice. Gene network analysis showed a coordinated expression of genes implicated in cell-mediated immune response, cell-to-cell signaling and interaction, and immune cell trafficking. The mRNA expression levels for the selected transcripts were verified using semi-quantitative RT-PCR method suggesting a panel of genes specific to CD8+ T cells differentially expressed between the responder and non-responder mice. Further studies are warranted to determine the potential of these identified genes as immunological biomarker to predict immunotherapy response.

Authors’ Affiliations

(1)
Urology, The University of Kansas Medical Center, Kansas City, USA
(2)
Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, USA
(3)
Internal Medicine, The University of Kansas Medical Center, Kansas City, USA

Copyright

© Dubey et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement